Introduction: To confirm the role of additional chromosomal abnormalities (ACAs)
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XUE Et al. of CML patients, 30% in the accelerated phase (AP) and 80% in the blast phase (BP). [1] [2] [3] Hence, ACAs are considered an intrinsic factor in the progression of CML patients with a negative impact on survival and prognosis. 2, 4, 5 ACAs were subdivided into major and minor routes, as initially proposed by Mitelman, based only on the frequencies of the ACAs. 6, 7 The major routes include +8, +Ph, +19 and isochromosome 17q, and the minor routes include −7, −17, +17, +21, −Y and t(3;21)(q26;q22).
The widespread use of TKIs has resulted in significant improvement in the survival of and prognoses for CML patients. However, the occurrence of resistance is more frequent. Many studies have
shown that kinase domain (KD) mutations are the main mechanism of CML resistance to TKIs. [8] [9] [10] [11] [12] [13] [14] Currently, more than 100 different KD mutations have been found since the discovery of the p. (T315I) mutation. 11, 15 The most common mutations are the P-loop muta- 17 There is an evidence that suggests CML patients with genetic instability are more likely to develop KD mutations. 18 However, some studies have shown that KD mutations do not correlate with ACAs and are randomly combined in CML patients, representing different resistance mechanisms. 12, 19 These views conflict with each other. We retrospectively analysed the ACAs and KD mutations of 219 CML patients admitted to our hospital to confirm the role of ACAs and KD mutations in the progression and outcomes of CML patients and the possible connection between them.
| MATERIAL S AND ME THODS

| Patients
Between Initial treatment regimens (hydroxyurea, interferon alpha or imatinib) were used for patients with or without ACAs and/or KD mutations.
When patients progressed and/or were detected as having resistance mutations, they changed to dasatinib or nilotinib. 
| BCR-ABL1 KD mutations analysis
The nested PCR method was combined with sequencing. TRIzol 
| Statistical analysis
When the total sample size of the random sample was less than 40 (n < 40) or the theoretical frequency was less than 1 (T < 1),
Fisher's exact test was used to compare differences between groups for categorical variables. Otherwise, the chi-squared test was used. Differences between groups of continuous variables were evaluated using a t test. The statistical analyses were performed with the SPSS 20.0 Software (SPSS Inc., Chicago, IL, USA)
and GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) statistical programs. The results were considered significant at P < 0.05.
| RE SULTS
| Baseline clinical characteristics of the study cohort
The baseline characteristics of all patients are summarized in Table 1 .
The median age of these patients at diagnosis was 44 years (range, 2-83 years). The patients were divided into two groups as follows:
group A, without ACAs or KD mutations and group B, with ACAs and/or KD mutations. No significant differences in baseline characteristics were found between the two groups, except for gender, with more men in group B than in group A (27/33 vs 110/186, 81.8% vs 59.1%, P = 0.013).
| Description of the ACAs
A total of 24 (11.0%) patients had ACAs in addition to the standard translocation, of which two patients (8.3%) showed the loss of the Y chromosome (−Y). The most common abnormality was trisomy 8, which emerged in four patients (Table 2) . A complex karyotype (defined as ≥3 chromosomal abnormalities) was detected in two cases (8.3%).
| KD mutations results
Kinase domain mutations analysis was performed only in patients with suboptimal, warning or failure TKI responses 23 (Table 3) . Four patients had KD mutations accompanied by ACAs (Figure 1 ).
| Outcomes of patients with ACAs and/or KD mutations
The incidence of CML progression was higher in group B than in group A (12/22 vs 2/143, 54.5% vs 1.4%, CI 95% P < 0.001) and was also higher in the KD mutations group than in the ACAs group (5/9 vs 4/20, 55.6% vs 20%, P = 0.046). The details of treatments, outcomes and appearance times of ACAs and/or KD mutations for patients with ACAs and/or KD mutations are shown in Figure 2 . For instance, patient 11 TA B L E 1 Characteristics of the 219 chronic myeloid leukaemia patients (as depicted in Figure 2A ) progressed after 1 year of taking imatinib.
Meanwhile, ACAs and a p.(E255K) mutation emerged, as shown in Figure 1A . Then, he switched to dasatinib, and more complicated ACAs were detected 2 years later ( Table 2 ). Patient 6 ( Figure 2B ) progressed to acute myelogenous leukaemia with maturation (AML-M2) after 5 months of treatment with hydroxyurea and interferon alpha.
So, he started taking imatinib 600 mg/d. Then, an E459K mutation was found after 4 months, and he had to change to nilotinib 400 mg twice a day but progressed to acute lymphocytic leukaemia (ALL) after 2 months.
| D ISCUSS I ON
To the best of our knowledge, ACAs are associated with CML pro- TA B L E 2 Additional chromosomal abnormalities of 24 chronic myeloid leukaemia patients route changes. In contrast, +19 exhibited a minor route change.
The frequencies of +8, +Ph and i(17q) were significantly reduced, despite keeping the position of major route changes. 3 Currently, trisomy 8, which was previously considered a poor prognostic factor, has been found to be a favourable factor when it appears as a single ACA and an adverse factor when combined with other abnormalities. 7 However, the four patients with trisomy 8 in our study progressed, including a single trisomy 8 abnormality.
Moreover, −Y was associated with increased survival in CML patients. 25 In this research, two patients with −Y maintain complete remission (CR).
In our study, KD mutations were identified in 13 of the 53 patients (24.5%) diagnosed with imatinib resistance. However, in other studies, the occurrence rate of KD mutations fluctuated between 22.4% and 73%. 8, 26 Thus, this ratio was slightly lower than the ratios in other reports. The most common KD mutation subtype was p.(Y253H) (n = 3; 23.07%), followed by p.(F359V) and p.(T315I) (n = 2; 15.38%), results that are similar to the study by Kayastha. This phenomenon coincided with the current study. Moreover, one study reported that the emergence of the 3q26.2 rearrangement had a high frequency of correlation with BCR-ABL1 mutations. 3 However, other studies showed that ACAs and KD mutations were randomly combined in CML patients, representing different resistance mechanisms. 12 There is a research that finds the acquisition of genetic alterations and genomic instability are induced by DNA damage, abnormal cell-cycle checkpoint activation and DNA repair in CML. Genomic instability includes aneuploidy, microsatellite instability, gross chromosomal aberrations and point mutations. 17 Visibly, both ACAs and KD mutations are subtypes of genomic instability, and some subtypes of KD mutations are more likely to coexist with ACAs.
In this study, we demonstrated that ACAs and KD mutations were closely related to CML progression. The incidence of CML progression was 12/22 (54.5%) in group B and 2/143 (1.4%) in group A (CI 95% P < 0.001). We also compared the role of ACAs and KD mutations in disease progression and found significant differences Finally, our study also showed the gender distribution of ACAs and/or KD mutations in CML patients. In this cohort, the percentage of males increased from 59.1% to 81.8% when comparing groups A and B. This gender distribution was also observed in other studies, which indicated that regular detection of ACAs and/or KD mutations was more important in male patients. 5, 7 In conclusion, we confirmed the role of ACAs and/or KD mutations in CML progression and demonstrated that both of these abnormalities were adverse factors in the outcome. F I G U R E 1 A, B, C and D show the four cases (11, 14, 20 and 24 in Table 2 ) with coexisting ACAs and KD mutations (using Adobe Photoshop CS5 and Adobe Illustrator CS5 graphics program)
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